Method of treating human preeclampsia employing resibufagenin

Details Method of treating human preeclampsia employing resibufagenin Method of treating human preeclampsia employing resibufagenin

2010-06-23

2011-12-20

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S172000, C514S026000, C514S025000, C536S004100

Reexamination Certificate

active

08080539

ABSTRACT:
A method of treating preeclampsia including administering a therapeutically effective dose of resibufagenin to a patient having preeclampsia. Effecting the determination of the presence of preeclampsia may be by determining whether there has been a substantial elevation in marinobufagenin which may be blood-derived or urine-derived and if such elevation does exist, concluding that preeclampsia does exist. The method may advantageously be practiced by employing urine, blood serum or blood plasma as the body specimen containing the protein in determining whether a patient has preeclampsia. In another embodiment, bufodienolide derivatives other than resibufagenin may be employed in lieu of thereof or in combination therewith. In another embodiment, resibufagenin analogues may be employed in the treatment of preeclampsia.

REFERENCES:
patent: 3585187 (1971-06-01), Heider et al.
patent: 5770376 (1998-06-01), Bagrov
patent: 6306845 (2001-10-01), Butler, Jr.
patent: 57056500 (1982-04-01), None
patent: 57056500 (1982-04-01), None
Derwent abstract of Fukuyama et al.; JP 57056500 A; Apr. 5, 1982.
Pridjian et al., “Neutralization of Marinobufagenin Normalizes Blood Pressure in a Rat Model of Preeclampsia”, Poster Session: Preeclampsia II (Friday, Mar. 26, 2004, 9:30 a.m.-11:30 a.m.), J. Soc Gynecol Investig, vol. 11, No. 2 (Supplement), Feb. 2004, 2 pages.
Williams et al., “vol. Expansion as a Proximate Cause of Preeclampsia in a Rat Model”, Basic Hypertension II, Journal of the American Society of Nephrology, vol. 13, Sep. 2002, Program and Abstracts Issue, 3 pages.
Chen et al., “vol. Expansion-Induced Changes in Renal Tubular Membrane Protein Phosphorylation”, Biochemical and Biophysical Research Communications, vol. 143, No. 1, Feb. 27, 1987, Academic Press, Inc. Harcourt Brace Jovanovich, Publishers, pp. 74-80.
Lopatin et al., “Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia”, Journal of Hypertension, vol. 17, No. 8, Aug. 1999, pp. 1179-1187.
Hayman et al., “Plasma from women with pre-eclampsia induces an in vitro alteration in the endothelium-dependent behaviour of myometrial resistance arteries”, BJOG, an International Journal of Obstretics and Gynaecology, vol. 107, No. 1, Jan. 2000, Edited by John M. Grant, pp. 108-115.
Graves, Steven W., “The Possible Role of Digitalislike Factors in Pregnancy-Induced Hypertension”, Hypertension Supplement, Workshop on Cation Transport and Natriuretic Factors, vol. 10, No. 5, Nov. 1987, pp. I-84 to I-86.
U.S. Appl. No. 10/109,203, filed Mar. 28, 2002, Jules B. Puschett.
U.S. Appl. No. 09/990,432, filed Nov. 21, 2001, Jules B. Puschett.
U.S. Appl. No. 60/444,730, filed Feb. 4, 2003, Jules B. Puschett.
Ianosi-Irimie et al., “A Rat Model of Preeclampsia,” Clinical and Experimental Hypertension, 8:605-617, 2005.
Vu et al., “Involvement of Marinobufagenin in a Rat Model of Human Preeclampsia,” Am J. Nephrol 2005;25:520-528.

Affiliated with

Also associated with

Rating

Method of treating human preeclampsia employing resibufagenin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating human preeclampsia employing resibufagenin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating human preeclampsia employing resibufagenin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4267799